SAN DIEGO, CA--(Marketwired - Aug 15, 2013) - The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, wishes to provide accurate information on Nuvilex's (
Larry Isen of the OTC Journal said, "I was both surprised and disgusted when I read an article, published on Seeking Alpha, claiming Nuvilex is worthless. Author Nicholas Kitonyi, who has written all of 14 articles and has a whopping 28 followers, has concluded Nuvilex has no value. Of the 14 articles he has published, none have been on a microcap stock. My publication, the OTC Journal, is in its 14th year of covering microcap stocks. I've published 127 editions this year alone.
"In order to get an article like this tagged to the ticker, Seeking Alpha must pre-approve it. My disappointment is with Seeking Alpha. I have found the community to be an excellent resource for unbiased information on stocks in the past, but this kind of activity makes one wonder if someone is being paid under the table on behalf of short sellers. It's a very transparent hatchet job that smacks of someone's agenda.
"There are a number of Seeking Alpha contributors who have attempted to present a fair, and more accurate portrayal of Nuvilex, but all submissions have been rejected.
"In his overview, the author provides a description of their products -- all of which were abandoned over two years ago in favor of a new direction.
"He then goes on to review the balance sheet, income statement, and cash flow, and suggests the lack of long term debt at the company is a negative. He doesn't mention NVLX completed a $1.5 million private placement at $.125 per share for an acquisition of oncology assets since the last financial statement was filed with the SEC. In Kitonyi's article he says, '...the company is putting too much into operations which leaves nothing for investments.' The recent funding and acquisition alone refutes his argument that the company can't raise money or isn't putting money into investments. This acquisition is potentially a multi-billion dollar investment.
"He then says the company has no cash flow from sales, so it's worthless. Of course they have no cash flow from sales -- they have no sales as they are in the process of trying to get a new therapy into a Phase III clinical trial. They won't have any sales for a long time.
"He suggests the stock is worthless due to lack of capital. Small companies like this tend to raise money in small amounts over long periods of time. This has been a public company for many years, and there's been about $40 million in paid-in capital over that time. I hardly think they are going out of business tomorrow."
Here are the true facts.
Nuvilex (NVLX) abandoned their eFoodSafety health care products in favor of an opportunity in biotech.
The company has acquired the global rights to develop cancer treatment therapies that are based on a unique live-cell encapsulation technology that helps cancer drugs to be far more efficient and less toxic. Nuvilex is preparing to get into Phase III trials for a Pancreatic Cancer therapy, and is taking the necessary steps to do so.
To date, approximately $30 million has been invested in the development of this live-cell encapsulation technology.
A Phase I/II trial that was conducted by SG Austria at the Rostock Medical University in Germany on 14 patients with advanced inoperable pancreatic cancer produced remarkable results. I was not there, but I have a copy of the study in my file, and it seems credible.
In that trial, cells capable of converting the well-known anticancer drug ifosfamide into its cancer-killing form were encapsulated using Nuvilex's live-cell encapsulation technology. Then, approximately 300 microcapsules were implanted in the blood supply near the pancreas and therefore the tumor itself. Following this, one-third of the normal dosage of ifosfamide was administered.
Historical data for Eli Lilly's Gemzar® (generic is Élan's Gemcitabine IV), at the time of the writing of the study report, with the same type of patients gave a median survival of 28 weeks with a one-year survival rate of 18%. Gemzar® is the only drug approved to date as a single agent for the treatment of advanced inoperable pancreatic cancer.
The patients given Nuvilex's treatment had a median survival of 44 weeks, and 36% survived for one year. With one-third the dosage of chemotherapy coupled with the use of the live-cell encapsulation technology, the effectiveness of the treatment was double that of Gemzar®. Furthermore, while serious toxicities (side effects) are associated with the use of Gemzar®, no serious drug-related toxicities were seen with the live-cell encapsulation/ifosfamide combination in the Phase I/II trial.
Annual global revenues for Gemzar® and its generic equivalent are estimated at about $1.4 billion. With an FDA approval for Nuvilex's live-cell encapsulation-based treatment, one could argue the market would value the therapy at 2 times the annual sales of Gemzar® -- a therapy worth $3 billion.
The global rights to develop and market the encapsulation technology for cancer therapies are the asset of Nuvilex.
I've been covering this company for many years, and of course was disappointed when eFoodSafety, their previous model, was abandoned. I used the products and liked them.
The positive side of the Nuvilex story is a cancer therapy that has $3 billion potential somewhere down the road. Zero revenue biotech stories find success all the time.
Consider Inovio (INO) -- featured in the OTC Journal at $.67 on May 21st. The stock recently traded to $3.03 (up 352%) on positive results on some trials performed in the lab on rats. It happens frequently in the bio tech sector. If you'd like to read the article, use the link below:
Seeking Alpha needs to examine its policies if it wants to remain credible.
To read all our most recent editions on the long term outlook for Nuvilex, go to:
About The OTC Journal: The OTC Journal is the longest running electronic newsletter committed to small and microcap stocks. Published continuously since 1998, the OTC Journal provides readers with short term trading ideas, long term ongoing coverage of worthy small and microcap companies, and overall market commentary.
The OTC Journal is also an investor relations firm that publishes a newsletter that provides a forum for issuers who wish to advertise their company. To read our publication, including information regarding our compensation, visit www.otcjournal.com. For ongoing updates an opinionated content on Nuvilex and many other small and micro cap stocks, visit www.otcjournal.com and input your email address.
About Nuvilex, Inc. (